38819-10-2 | 9-(Beta-d-arabinofuranosyl)guanine

Packsize	Purity	Availability	Price	Discounted Price
50mg	95%	in stock	$42.00	$29.00
250mg	95%	in stock	$65.00	$45.00
1g	95%	in stock	$163.00	$114.00
5g	95%	in stock	$660.00	$462.00

Description

• Catalog Number: AB50046
• Chemical Name: 9-(Beta-d-arabinofuranosyl)guanine
• CAS Number: 38819-10-2
• Molecular Formula: C10H13N5O5
• Molecular Weight: 283.2407
• MDL Number: MFCD12912394
• SMILES: OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1cnc2c1nc(N)[nH]c2=O

Computed Properties

• Complexity: 446
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 2
• XLogP3: -1.9

Literature

• Induction of fetal hemoglobin and ABCB1 gene expression in 9-β-D-arabinofuranosylguanine-resistant MOLT-4 cells.

  Cancer chemotherapy and pharmacology 20110901

• In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.

  Blood 20110825

• Activation of guanine-β-D-arabinofuranoside and deoxyguanosine to triphosphates by a common pathway blocks T lymphoblasts at different checkpoints.

  Experimental cell research 20101210

• A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.

  Oncology reports 20100201

• Intravitreal crystalline drug delivery for intraocular proliferation diseases.

  Investigative ophthalmology & visual science 20100101

• Nelarabine in the treatment of refractory T-cell malignancies.

  Clinical Medicine Insights. Oncology 20100101

• Acute cytotoxicity of arabinofuranosyl nucleoside analogs is not dependent on mitochondrial DNA.

  Experimental cell research 20090910

• Synthesis of 9-beta-d-arabinofuranosylguanine by combined use of two whole cell biocatalysts.

  Bioorganic & medicinal chemistry letters 20090801

• Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.

  OncoTargets and therapy 20090101

• Reduced levels of mitochondrial DNA increases the toxicity of 9-beta-D-arabinofuranosylguanine (araG).

  Nucleosides, nucleotides & nucleic acids 20080601

• Nelarabine.

  Drugs 20080101

• Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

  Therapeutics and clinical risk management 20071201

• Nelarabine: a novel purine antimetabolite antineoplastic agent.

  Clinical therapeutics 20070901

• Depletion of mitochondrial DNA by down-regulation of deoxyguanosine kinase expression in non-proliferating HeLa cells.

  Experimental cell research 20070715

• Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

  Blood 20070615

• Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes.

  Biochemical and biophysical research communications 20070615

• Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.

  Cancer chemotherapy and pharmacology 20070501

• Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.

  Bioorganic & medicinal chemistry 20070415

• Enhanced toxicity of purine nucleoside analogs in cells expressing Drosophila melanogaster nucleoside kinase mutants.

  Gene therapy 20070101

• Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.

  Leukemia & lymphoma 20070101

• Nelarabine: a new purine analog in the treatment of hematologic malignancies.

  Reviews on recent clinical trials 20060901

• Nelarabine: efficacy in the treatment of clinical malignancies.

  Future oncology (London, England) 20060801

• Phosphorylation of 9-beta-D-arabinofuranosylguanine monophosphate by Drosophila melanogaster guanylate kinase.

  Biochemical pharmacology 20051001

• Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.

  Journal of medicinal chemistry 20040422

• Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides.

  Nucleosides, nucleotides & nucleic acids 20040101

• Mechanisms for T-cell selective cytotoxicity of arabinosylguanine.

  Blood 20030901

• The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G.

  Biochemical pharmacology 20030901

• Effects of 9-beta-D-arabinofuranosylguanine on mitochondria in CEM T-lymphoblast leukemia cells.

  Biochemical and biophysical research communications 20030808

• Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy.

  Biochemical pharmacology 20030801

• Resistance to mitochondrial- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-beta-D-arabinofuranosylguanosine.

  Biochemical and biophysical research communications 20021101

• Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.

  Cancer research 20020601

• Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity.

  Biochemical and biophysical research communications 20020524

• Telomerase-inhibitory effects of sugar-modified nucleotide analogs.

  Nucleic acids research. Supplement (2001) 20020101

• Identification and characterization of human deoxyguanosine kinase cDNA fragments.

  Cancer letters 20010920

• Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells.

  Biochemical and biophysical research communications 20010706

• Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

  Leukemia 20010601

• Anti-herpesvirus activity profile of 4'-thioarabinofuranosyl purine and uracil nucleosides and activity of 1-beta-D-2'-fluoro-4'-thioarabinofuranosyl guanine and 2,6-diaminopurine against clinical isolates of human cytomegalovirus.

  Antiviral research 19980801

• A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.

  Journal of medicinal chemistry 19970704